UBS Group’s PAVmed PAVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $760 | Sell |
75
-7,252
| -99% | -$68.6K | ﹤0.01% | 9754 |
|
|
2025
Q4 | $48.6K | Buy |
7,327
+7,298
| +25,166% | +$83.3K | ﹤0.01% | 7231 |
|
|
2025
Q3 | $375 | Sell |
29
-263
| -90% | -$3.91K | ﹤0.01% | 9712 |
|
|
2025
Q2 | $5.25K | Buy |
292
+253
| +649% | +$5.07K | ﹤0.01% | 9193 |
|
|
2025
Q1 | $835 | Sell |
39
-387
| -91% | -$8.02K | ﹤0.01% | 9645 |
|
|
2024
Q4 | $8.02K | Buy |
+426
| New | +$12.6K | ﹤0.01% | 8433 |
|
|
2024
Q3 | – | Sell |
-160
| Closed | -$4.91K | – | 9351 |
|
|
2024
Q2 | $3.91K | Buy |
+160
| New | +$7.98K | ﹤0.01% | 8149 |
|
|
2024
Q1 | – | Sell |
-201
| Closed | -$24.8K | – | 9839 |
|
|
2023
Q4 | $24.8K | Buy |
201
+198
| +6,600% | +$23.3K | ﹤0.01% | 6971 |
|
|
2023
Q3 | $354 | Hold |
3
| – | – | ﹤0.01% | 8558 |
|
|
2023
Q2 | $490 | Sell |
3
-47
| -94% | -$9.4K | ﹤0.01% | 8211 |
|
|
2023
Q1 | $8.4K | Buy |
50
+24
| +92% | +$5.05K | ﹤0.01% | 7729 |
|
|
2022
Q4 | $5.61K | Sell |
26
-66
| -72% | -$24.9K | ﹤0.01% | 9155 |
|
|
2022
Q3 | $35K | Buy |
92
+82
| +820% | +$46.5K | ﹤0.01% | 6696 |
|
|
2022
Q2 | $4K | Sell |
10
-30
| -75% | -$14.5K | ﹤0.01% | 9099 |
|
|
2022
Q1 | $25K | Sell |
40
-5
| -11% | -$3.72K | ﹤0.01% | 7200 |
|
|
2021
Q4 | $50K | Buy |
45
+7
| +18% | +$15.2K | ﹤0.01% | 6893 |
|
|
2021
Q3 | $145K | Buy |
+38
| New | +$120K | ﹤0.01% | 5565 |
|
|
2021
Q2 | – | Sell |
-99
| Closed | -$197K | – | 9695 |
|
|
2021
Q1 | $197K | Buy |
99
+84
| +560% | +$126K | ﹤0.01% | 5501 |
|
|
2020
Q4 | $15K | Buy |
15
+14
| +1,400% | +$12K | ﹤0.01% | 7168 |
|
|
2020
Q3 | $1K | Sell |
1
-25
| -96% | -$22.2K | ﹤0.01% | 7818 |
|
|
2020
Q2 | $24K | Buy |
+26
| New | +$26K | ﹤0.01% | 6434 |
|
|
2020
Q1 | – | Sell |
-43
| Closed | -$23K | – | 8279 |
|
|
2019
Q4 | $23K | Buy |
+43
| New | +$17.9K | ﹤0.01% | 6794 |
|
|
2019
Q3 | – | Sell |
-5
| Closed | -$2K | – | 8181 |
|
|
2019
Q2 | $2K | Buy |
+5
| New | +$2.64K | ﹤0.01% | 7626 |
|
|
2018
Q4 | – | Sell |
-11
| Closed | -$6K | – | 8219 |
|
|
2018
Q3 | $6K | Buy |
11
+8
| +267% | +$4.88K | ﹤0.01% | 7410 |
|
|
2018
Q2 | $1K | Sell |
3
-19
| -86% | -$11.6K | ﹤0.01% | 7830 |
|
|
2018
Q1 | $16K | Buy |
+22
| New | +$18.9K | ﹤0.01% | 6571 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | -$2K | – | 7891 |
|
|
2017
Q1 | $2K | Buy |
+1
| New | +$2.69K | ﹤0.01% | 7296 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | -$4K | – | 7964 |
|
|
2016
Q3 | $4K | Buy |
+1
| New | +$6.36K | ﹤0.01% | 7207 |
|
Other funds holding PAVM
TSC
VCM
VFT
TRCT
SS
UBS Group's PAVM Position: Q1 2026 in Review
UBS Group reduced its PAVmed (PAVM) stake by 99% in Q1 2026, selling an estimated $68.6K and leaving 75 shares worth $760. The position accounts for ﹤0.01% of the portfolio, ranked #9754.
UBS Group first reported a position in PAVM in Q3 2016 and has held it in 28 quarters since. The position peaked at $197K in Q1 2021. 20 funds tracked by Wall St. Rank hold PAVM as of Q1 2026.
- UBS Group held 75 shares of PAVmed worth $760 as of Q1 2026.
- UBS Group sold 7,252 PAVmed shares in Q1 2026, an estimated $68.6K.
- PAVmed made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9754 holding.
- UBS Group first reported a position in PAVmed in Q3 2016 and has held it in 28 quarters since.
- UBS Group's PAVmed position peaked at $197K in Q1 2021.
- 20 funds tracked by Wall St. Rank held PAVmed as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.